MARKET

CANF

CANF

Can-Fite BioPharma Ltd.
AMEX
1.435
-0.034
-2.34%
After Hours: 1.540 +0.105 +7.32% 16:25 11/20 EST
OPEN
1.480
PREV CLOSE
1.469
HIGH
1.533
LOW
1.420
VOLUME
16.83K
TURNOVER
--
52 WEEK HIGH
12.30
52 WEEK LOW
1.420
MARKET CAP
4.35M
P/E (TTM)
-0.5787
1D
5D
1M
3M
1Y
5Y
1D
Can-Fite BioPharma Ltd. Completes Dosing in Phase III Psoriasis Study Interim Cohort with Results Expected Q1 2027
NASDAQ · 3d ago
Can-Fite Reports Completion of Dosing in Phase III Psoriasis Study
TipRanks · 4d ago
Can-Fite Biopharma Completes Treatment Of First 247 Patients In Its Phase III Study Evaluating Piclidenoson For Moderate-To-Severe Plaque Psoriasis; Expects Results Of Pre-Specified Interim Analysis In Q1 2027
Benzinga · 4d ago
Weekly Report: what happened at CANF last week (1109-1113)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/13 21:05
Can-Fite’s Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study
NASDAQ · 11/13 01:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/12 21:05
Can-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical Study
NASDAQ · 11/12 14:46
More
About CANF
Can-Fite BioPharma Ltd. is an Israel-based clinical-stage biopharmaceutical company engaged in the development of small-molecule therapeutic products targeting cancer, liver diseases, inflammatory disorders, and metabolic conditions. The Company’s proprietary platform is based on the A3 adenosine receptor (A3AR) as a therapeutic target. Its product pipeline includes Piclidenoson, Namodenoson, and CF602, which are being evaluated for indications including psoriasis, hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis (MASH), pancreatic cancer, obesity, Lowe syndrome, and erectile dysfunction. The Company conducts research, clinical development, licensing, and commercialization activities through its drug development programs and strategic collaborations.

Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.